222 related articles for article (PubMed ID: 31176047)
21. Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma.
Xiang M; English DP; Kidd EA
Gynecol Oncol; 2019 Sep; 154(3):487-494. PubMed ID: 31257010
[TBL] [Abstract][Full Text] [Related]
22. Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer.
Forsse D; Berg HF; Bozickovic O; Engerud H; Halle MK; Hoivik EA; Woie K; Werner HMJ; Haldorsen IS; Trovik J; Krakstad C
Gynecol Oncol; 2021 Feb; 160(2):396-404. PubMed ID: 33317908
[TBL] [Abstract][Full Text] [Related]
23. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
Alvarez Secord A; Havrilesky LJ; Bae-Jump V; Chin J; Calingaert B; Bland A; Rutledge TL; Berchuck A; Clarke-Pearson DL; Gehrig PA
Gynecol Oncol; 2007 Nov; 107(2):285-91. PubMed ID: 17688923
[TBL] [Abstract][Full Text] [Related]
24. Should the Optimal Adjuvant Treatment for Patients With Early-Stage Endometrial Cancer With High-Intermediate Risk Factors Depend on Tumor Grade?
Lan C; Huang X; Huang Q; Wang Y; Gu H; Li Y; Liu J
Int J Gynecol Cancer; 2015 Oct; 25(8):1445-52. PubMed ID: 26397067
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for lymph node metastases in women with endometrial cancer: A population-based, nation-wide register study-On behalf of the Swedish Gynecological Cancer Group.
Stålberg K; Kjølhede P; Bjurberg M; Borgfeldt C; Dahm-Kähler P; Falconer H; Holmberg E; Staf C; Tholander B; Åvall-Lundqvist E; Rosenberg P; Högberg T
Int J Cancer; 2017 Jun; 140(12):2693-2700. PubMed ID: 28340503
[TBL] [Abstract][Full Text] [Related]
26. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
Ma SK; Zhang HT; Sun YC; Wu LY
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
[TBL] [Abstract][Full Text] [Related]
27. Prognosis for endometrial cancer patients treated with systematic pelvic and para-aortic lymphadenectomy followed by platinum-based chemotherapy.
Sueoka K; Umayahara K; Abe A; Usami T; Yamamoto A; Nomura H; Matoda M; Okamoto S; Omatsu K; Kondo E; Kato K; Takeshima N
Int J Gynecol Cancer; 2015 Jan; 25(1):81-6. PubMed ID: 25347094
[TBL] [Abstract][Full Text] [Related]
28. Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma.
Hiura M; Nogawa T; Matsumoto T; Yokoyama T; Shiroyama Y; Wroblewski J
Int J Gynecol Cancer; 2010 Aug; 20(6):1000-5. PubMed ID: 20683408
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant therapy for early endometrial cancer - who benefits the most from a radiation therapy?
Michalak M; Warenczak Florczak Z; Staszewska-Nowak A; Roszak A
Ginekol Pol; 2020; 91(1):6-12. PubMed ID: 32039461
[TBL] [Abstract][Full Text] [Related]
30. Influence of body mass index on clinicopathologic features, surgical morbidity and outcome in patients with endometrial cancer.
Akbayır O; Corbacıoglu Esmer A; Numanoglu C; Cılesız Goksedef BP; Akca A; Bakır LV; Kuru O
Arch Gynecol Obstet; 2012 Nov; 286(5):1269-76. PubMed ID: 22729137
[TBL] [Abstract][Full Text] [Related]
31. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.
Bosse T; Peters EE; Creutzberg CL; Jürgenliemk-Schulz IM; Jobsen JJ; Mens JW; Lutgens LC; van der Steen-Banasik EM; Smit VT; Nout RA
Eur J Cancer; 2015 Sep; 51(13):1742-50. PubMed ID: 26049688
[TBL] [Abstract][Full Text] [Related]
32. Impact of different adjuvant treatment approaches on survival in stage III endometrial cancer: A population-based study.
van Weelden WJ; Reijnen C; Eggink FA; Boll D; Ottevanger PB; van den Berg HA; van der Aa MA; Pijnenborg JMA
Eur J Cancer; 2020 Jul; 133():104-111. PubMed ID: 32454416
[TBL] [Abstract][Full Text] [Related]
33. Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes.
Smart A; Buscariollo D; Alban G; Buzurovic I; Cheng T; Pretz J; Krechmer B; King M; Lee L
Int J Gynecol Cancer; 2020 Dec; 30(12):1908-1914. PubMed ID: 32655012
[TBL] [Abstract][Full Text] [Related]
34. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
Alektiar KM; Venkatraman E; Chi DS; Barakat RR
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
[TBL] [Abstract][Full Text] [Related]
35. It is time to implement molecular classification in endometrial cancer.
Bruno V; Logoteta A; Chiofalo B; Mancini E; Betti M; Fabrizi L; Piccione E; Vizza E
Arch Gynecol Obstet; 2024 Mar; 309(3):745-753. PubMed ID: 37410149
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion.
Son J; Chambers LM; Carr C; Michener CM; Yao M; Beavis A; Yen TT; Stone RL; Wethington SL; Fader AN; Burkett WC; Richardson DL; Staley AS; Ahn S; Gehrig PA; Torres D; Dowdy SC; Sullivan MW; Modesitt SC; Watson C; Veade A; Ehrisman J; Havrilesky L; Secord AA; Loreen A; Griffin K; Jackson A; Viswanathan A; Ricci S
Int J Gynecol Cancer; 2020 Nov; 30(11):1738-1747. PubMed ID: 32771986
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant therapy in stage III endometrial cancer: treatment outcomes and survival. a single-institution retrospective study.
Kuku S; Williams M; McCormack M
Int J Gynecol Cancer; 2013 Jul; 23(6):1056-64. PubMed ID: 23765205
[TBL] [Abstract][Full Text] [Related]
38. Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer.
Philp L; Tannenbaum S; Haber H; Saini A; Laurent JS; James K; Feltmate CM; Russo AL; Growdon WB
Gynecol Oncol; 2021 Feb; 160(2):389-395. PubMed ID: 33358198
[TBL] [Abstract][Full Text] [Related]
39. The prognostic significance of aortic lymph node metastasis in endometrial cancer: Potential implications for selective aortic lymph node assessment.
Cosgrove CM; Cohn DE; Rhoades J; Felix AS
Gynecol Oncol; 2019 Jun; 153(3):505-510. PubMed ID: 30935714
[TBL] [Abstract][Full Text] [Related]
40. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy.
Hochreiter A; Kelly JR; Young MR; Litkouhi B; Black JD; Stromberger C; Higgins S; Schwartz PE; Damast S
Int J Gynecol Cancer; 2020 Jan; 30(1):48-55. PubMed ID: 31722964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
